ATE105842T1 - Von thrombin abstammende polypeptid- zusammensetzungen und methoden für ihre benutzung. - Google Patents

Von thrombin abstammende polypeptid- zusammensetzungen und methoden für ihre benutzung.

Info

Publication number
ATE105842T1
ATE105842T1 AT87907652T AT87907652T ATE105842T1 AT E105842 T1 ATE105842 T1 AT E105842T1 AT 87907652 T AT87907652 T AT 87907652T AT 87907652 T AT87907652 T AT 87907652T AT E105842 T1 ATE105842 T1 AT E105842T1
Authority
AT
Austria
Prior art keywords
thrombin
receptor
occupancy
signals
derivatives
Prior art date
Application number
AT87907652T
Other languages
English (en)
Inventor
Darrell H Carney
Kevin C Glenn
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25451374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE105842(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE105842T1 publication Critical patent/ATE105842T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT87907652T 1986-10-31 1987-10-30 Von thrombin abstammende polypeptid- zusammensetzungen und methoden für ihre benutzung. ATE105842T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/925,201 US5352664A (en) 1986-10-31 1986-10-31 Thrombin derived polypeptides; compositions and methods for use

Publications (1)

Publication Number Publication Date
ATE105842T1 true ATE105842T1 (de) 1994-06-15

Family

ID=25451374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87907652T ATE105842T1 (de) 1986-10-31 1987-10-30 Von thrombin abstammende polypeptid- zusammensetzungen und methoden für ihre benutzung.

Country Status (7)

Country Link
US (3) US5352664A (de)
EP (1) EP0328552B2 (de)
JP (1) JP3054150B2 (de)
AT (1) ATE105842T1 (de)
AU (1) AU8239987A (de)
DE (1) DE3789870T3 (de)
WO (1) WO1988003151A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630572B1 (en) 1986-10-31 2003-10-07 The Board Of Regents, University Of Texas Syatems Thrombin derived polypeptides: compositions and methods for use
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
FI912858A0 (fi) * 1988-12-20 1991-06-13 Jolla Cancer Res Found Polypeptidpolymerkonjugat aktiva vid botande av saor.
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
US5120829A (en) * 1989-03-20 1992-06-09 La Jolla Cancer Research Foundation Hydrophobic attachment site for adhesion peptides
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5807828A (en) * 1989-06-16 1998-09-15 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5686569A (en) * 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
EP0775742A3 (de) * 1989-09-29 1998-01-14 La Jolla Cancer Research Foundation Inhibierung von TGF-beta zur Verhinderung von extrazellulärer Matrixanhäufung
US7214375B1 (en) 1989-09-29 2007-05-08 La Jolla Cancer Research Foundation Methods of decreasing the accumulation of extracellular matrix associated with glomerulonephritis with anti-TGF-β-specific antibodies
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US7119182B1 (en) 1991-02-19 2006-10-10 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
EP0667783B1 (de) * 1991-11-07 1999-04-21 The University Of Southern California Zusammensetzungen und verfahren zur verhinderung der adhäsionbildung
EP0632829A1 (de) * 1992-03-02 1995-01-11 Biogen, Inc. Thrombin-Rezeptor Antagonisten
DK83092D0 (da) * 1992-06-24 1992-06-24 Unes As Fremgangsmaade til udvinding af thrombin
IL106197A (en) * 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5516889A (en) * 1993-06-21 1996-05-14 University Technologies International, Inc. Synthetic thrombin receptor peptides
US5795780A (en) * 1993-06-23 1998-08-18 Bristol-Myers Squibb Company Method of use of autologous thrombin blood fraction in a cell culture with keratinocytes
US5716789A (en) * 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
FR2722509B1 (fr) * 1994-07-15 1996-09-20 Pasteur Institut Identification de genes codant pour des proteines ayant une activite d'esterase dans differentes souches de mycoplasma mycoides
IL114140A (en) * 1995-06-14 2000-06-01 Hadasit Med Res Service Anti-metastatic and anti-angiogenetic pharmaceutical compositions
IL114890A (en) 1995-08-10 1999-08-17 Hadasit Med Res Service Method and kits for evaluating the metastatic tendency of tumor cells
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6274090B1 (en) 1998-08-05 2001-08-14 Thermogenesis Corp. Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
IL125698A (en) * 1998-08-07 2007-03-08 Hadasit Med Res Service Use of molecules associated with protease activated receptors for the preparation of pharmaceutical compositions and pharmaceutical compositions comprising them
IL127174A0 (en) 1998-11-20 1999-09-22 Almog Projects Ltd Sewage treatment facility and method
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6472162B1 (en) 1999-06-04 2002-10-29 Thermogenesis Corp. Method for preparing thrombin for use in a biological glue
US7053043B1 (en) * 1999-07-23 2006-05-30 Yeda Research And Development Co.Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
GB9925005D0 (en) 1999-10-22 1999-12-22 Univ Nottingham The treatment of wounds
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
AU2001276977B2 (en) 2000-07-19 2005-05-19 Orthologic Corp. Stimulation of bone growth with thrombin peptide derivatives
DE60105772T2 (de) 2000-07-20 2006-02-16 Board of Regents, The University of Texas System, Austin Stimulation des knorpelwachstums mit agonisten des nicht-proteolytisch aktivierten thrombin rezeptors
CN100509055C (zh) * 2001-07-27 2009-07-08 奥索洛吉艾斯有限公司 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
EP1467749B1 (de) * 2002-01-16 2011-04-06 Capstone Therapeutics Corp. Thrombin-derivierten peptiden zur förderung von herzgewebsreparatur
CA2491135A1 (en) * 2002-07-02 2004-01-15 The Board Of Regents, The University Of Texas System Thrombin peptide derivative dimers
EP1539214A4 (de) * 2002-07-02 2008-01-02 Orthologic Corp Thrombinpeptidderivate
JP2006526025A (ja) 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
US20080019955A1 (en) * 2003-12-30 2008-01-24 Bioactive Polymers Ab Surface Protection of Exposed Biological Tissues
SE0303588D0 (sv) 2003-12-30 2003-12-30 Bioactive Polymers Ab C O Lund Surface protection of exposed biological tissues
DK1559431T3 (da) * 2003-12-31 2007-07-30 Orthologic Corp Farmaceutisk sammensætning til thrombinpeptidderivater
EP1756139A4 (de) 2004-03-12 2009-07-29 Entremed Inc Antiangiogene mittel
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
JP2008510726A (ja) * 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
US20070275874A1 (en) * 2004-09-03 2007-11-29 Yale University Use of Leptin in Wound Healing
WO2007035406A1 (en) * 2005-09-16 2007-03-29 Orthologic Corp. Antibodies to complementary peptides of thrombin or portions thereof
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
CA2663547C (en) * 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
WO2008124172A1 (en) * 2007-04-10 2008-10-16 The Board Of Regents, The University Of Texas System Combination therapy for chronic dermal ulcers
WO2009120304A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
CA2722620A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
JP2011515471A (ja) * 2008-03-26 2011-05-19 オーソロジック コーポレイション 急性心筋梗塞を処置するための方法
US8952129B2 (en) * 2008-03-26 2015-02-10 The Board Of Regents Of The University Of Texas System Method of treating degenerative diseases
US20110319340A1 (en) * 2008-09-19 2011-12-29 The Board Of Regents, The University Of Texas System Methods for treating cancer
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
CA2802176A1 (en) 2010-06-11 2011-12-15 The Board Of Regents, The University Of Texas System Methods of mitigating effects of radiation and reducing the risk of systemic infection
US20130101574A1 (en) * 2010-06-11 2013-04-25 Darrell H. Carney Methods of using thrombin peptide derivatives
US10220078B2 (en) * 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3171072D1 (en) * 1981-06-25 1985-07-25 Stroetmann M Serapharm Enriched plasma derivative for promoting wound sealing and wound covering
DE3214337C2 (de) * 1982-04-19 1984-04-26 Serapharm - Michael Stroetmann, 4400 Münster Resorbierbares Flachmaterial zum Abdichten und Heilen von Wunden und Verfahren zu dessen Herstellung
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4515637A (en) * 1983-11-16 1985-05-07 Seton Company Collagen-thrombin compositions
US4988621A (en) 1985-05-24 1991-01-29 La Jolla Cancer Research Foundation Peptides in cell detachment and aggregation
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors

Also Published As

Publication number Publication date
WO1988003151A3 (en) 1988-07-28
US6627731B1 (en) 2003-09-30
EP0328552B1 (de) 1994-05-18
JP3054150B2 (ja) 2000-06-19
EP0328552B2 (de) 1997-05-02
JPH02501028A (ja) 1990-04-12
DE3789870T2 (de) 1994-09-01
WO1988003151A2 (en) 1988-05-05
EP0328552A1 (de) 1989-08-23
AU8239987A (en) 1988-05-25
DE3789870D1 (de) 1994-06-23
DE3789870T3 (de) 1997-10-02
US5352664A (en) 1994-10-04
US5500412A (en) 1996-03-19

Similar Documents

Publication Publication Date Title
DE3789870D1 (de) Von thrombin abstammende polypeptid-zusammensetzungen und methoden für ihre benutzung.
UA13321A (uk) Спосіб експресії мітогеhhого білка еhдотеліальhих клітиh людиhи
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
PT917571E (pt) Gene relacionado com agouti
DE69029657D1 (de) Menschliches cytokin, interleukin-9
ATE442373T1 (de) Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
ATE458050T1 (de) Promotion oder inhibition von angiogenese und kardiovaskularisation
FI951612A0 (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
PT80631A (de) Verfahren zur herstellung von thrombin-inhibitoren
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
EP0205475A4 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
ATE372384T1 (de) Protein-tyrosin-phosphatase ptp-s31
DE68917837D1 (de) Peptid-Verbindungen.
CA2227046A1 (en) Peptides for use in wound treatment
ATE363488T1 (de) Zusammensetzungen von stammzellfaktor (scf)- analogen und auf diese bezogene verfahren
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
DE69615185D1 (de) Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
DE59105231D1 (de) Klonierung und Überexpression von Glucose-6-Phosphat-Dehydrogenase aus Leuconostoc dextranicus.
DE60038740D1 (de) Stimulierung oder hemmung von angiogenese und herzvaskularisierung
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
EP0502876B1 (de) Neue blutgerinnselauflösende proteine und ihre herstellung aus dem blutegel hirudo medicinalis
FI954889A7 (fi) Proteiini, jolla on TPO-aktiviteetti
EP0312283A3 (de) Di- oder Tripeptid-Renin-Inhibitoren, die Lactam-Konformationsrestriktion in ACHPA enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties